Compare AbCellera Biologics Inc (ABCL) vs GE Aerospace (GE) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

GE trades at $378.68, up 0.31% today, with a bullish technical signal from moving averages and strong support at $375. The company reported three consecutive quarterly earnings beats, with Q1 2026 EPS of $1.86 exceeding expectations. Revenue grew to $45.86 billion in 2025, while net income margin improved to 17.86%. Recent news highlights robust order growth in aerospace and defense contracts, including a U.S. Air Force engine development deal announced May 19, 2026.

Outlook remains positive with a consensus price target of $394.33, though high valuation ratios (P/E 47.04) and rising debt levels pose risks. Aerospace demand and defense contracts support growth, but investors should monitor execution on expansion investments and macroeconomic pressures on aviation.